Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
A phase I study of monohydroxyethylrutoside in healthy volunteers
A.M. Willems
, A.M. Bruynzeel
*
, M.A. Kedde
, C.J. van Groeningen
, A. Bast
, W.J.F. van der Vijgh
*
Corresponding author for this work
NUTRIM - Institute of Nutrition and Translational Research in Metabolism
CARIM - Cardiovascular Research Institute Maastricht
Research output
:
Contribution to journal
›
Article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'A phase I study of monohydroxyethylrutoside in healthy volunteers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Healthy Volunteers
100%
Cmax
100%
Phase I Study
100%
Placebo
66%
Cancer Patients
66%
In Cancer
66%
Pharmacokinetics
66%
Doxorubicin-induced Cardiotoxicity
66%
Dextrose
66%
Dose Level
66%
Randomized Trial
33%
Antitumor Effect
33%
Doxorubicin
33%
Phase II Study
33%
Dose Escalation
33%
Protective Properties
33%
Starting Dose
33%
MonoHER
33%
IV Infusion
33%
Safe Dose
33%
Flavonols
33%
Pharmacology, Toxicology and Pharmaceutical Science
Normal Human
100%
Side Effect
100%
Doxorubicin
100%
Placebo
66%
Malignant Neoplasm
66%
Cardiotoxicity
66%
Pharmacokinetics
66%
Flavonol
33%
INIS
doses
100%
values
37%
side effects
37%
auc
37%
doxorubicin
37%
levels
25%
patients
25%
cancer
25%
mice
25%
protection
12%
in vivo
12%
in vitro
12%
infusion
12%